📰 Sclerosis Complex News
Page 2 - Sclerosis Complex News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sclerosis Complex. Real-time updates on events, politics, business and more.
April 20, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the ... GW Pharmaceuticals plcApril 20, 2021 GMT – Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines 1 – LONDON, April 20, 20...
April 20, 2021
GW Pharmaceuticals plc: GW Pharmaceuticals receives European Commission approval for EPIDYOLEX (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex - LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation applicat...
February 26, 2021
GW Pharmaceuticals plc GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex – If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – LONDON, Feb. 26, 2021 (GLOBE NE...
February 26, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.